SY
SymBio Pharmaceuticals Limited
SYMQY · OTC
$0.56 +0.00% (+$0.00)
Market Cap ¥4.15B
P/E Ratio -
Div. Yield -
ROE 937.62%
Bulios Fair Price
$0.72
29.1% upside
Current Price
$0.56
Undervalued Fair Value Overvalued
According to Bulios Fair Price, SYMQY is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
3/9Valuation
49 /100
Fair P/S 3.63x
P/E N/A
EV/EBITDA N/A
Growth
0 /100
Declining Rev. growth 48.45%
Book val. growth 46.91%
EPS growth N/A
Profitability
22 /100
Weak Gross margin 73.70%
Net margin 533.87%
Op. margin 524.67%
Quality
8 /100
Poor ROIC 2,386.20%
ROE 937.62%
ROA 322.33%
Debt
9 /100
High Current ratio 0.75x
Int. coverage -104.28x
Debt/Equity N/A
Stability
51 /100
Moderate Beta 0.53x
Rev. volatility 6.92%
EPS volatility 129.94%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about SYMQY
Online
Sector
Healthcare
Industry
Medical - Pharmaceuticals
CEO
Fuminori Yoshida
Employees
91
Headquarters
Tokyo
Upcoming events
29 OCT
Earnings
Upcoming earnings report